צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Zymeworks Inc. (ZYME)

The development of multi-specific antibodies and the success of zanidatamab establish a foundation for growth, as confirmed by the TTM revenue growth rate for Zymeworks Inc. (ZYME). Management's strategic focus on oncology and the launch of targeted therapies for solid tumors strengthen the financial base. Meanwhile, the 97.40 metric determines this level, capturing the final revenue dynamics relative to operating expenses.
Zymeworks (ZYME) - פילוחי מדדים ודוחות פיננסיים

The development of cancer immunotherapy through strategic alliances with pharma behemoths directly impacts the rolling annual sales growth rate, reflecting the effectiveness of licensing agreements. The current value of 97.40 is calculated as the percentage deviation of TTM revenue from the same period last year, allowing investors to assess the business scaling pace and the fundamental resilience of Zymeworks Inc. (ZYME) amid industry cycles.